David C. Hastings - 08 Jan 2026 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Chief Financial Officer
Signature
/s/ Christopher Galletta, attorney-in-fact
Issuer symbol
TRVI
Transactions as of
08 Jan 2026
Net transactions value
$0
Form type
4
Filing time
12 Jan 2026, 16:05:09 UTC
Previous filing
30 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
HASTINGS DAVID C Chief Financial Officer C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN /s/ Christopher Galletta, attorney-in-fact 12 Jan 2026 0001237401

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Award $0 +375,000 $0.000000 375,000 08 Jan 2026 Common Stock 375,000 $11.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on January 8, 2026. The 375,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on January 8, 2027 and as to the remaining 75% of the shares in equal monthly installments thereafter through January 8, 2030.